Platelet membrane-coated drug delivery system
Patent Number: WO2017027760
Executive Summary:
Clinical Applications:
General Description:
The present invention describes the method to construct and the use of a platelet membrane-coated core-shell nanovehicle ("PM-NV") system, consisting of an inner core carrying a small molecule drug, encapsulated in outer shell coated with platelet cell membrane. Platelet is a component of the blood responsible to maintain hemostasis by preventing excessing bleeding in case of blood vessel injury. Platelets could also interact with circulating tumor cells (CTCs) and have a role in providing signals to cancer cells for efficient metastasis. Because of the high affinity between the PM and malignant cells, the PM-NV offers the advantage to specifically target cancer cells to deliver multiple and sequentially active compounds. By coating with tumor-derived PM, the nanocarriers aggregate on the surface of cancer cells. When the outer shell is associated with extracellularly active compounds, PM-NV promotes cell death signaling pathways through the interaction of these compounds with molecules that are abundant on the surface of cancer cells. The PM-NV can be internalized intracellularly by endocytosis. Upon acidity in the lyso-endosome compartment, the PM-NV are degraded releasing the second compound that could act intracellularly to induce cell death. This invention reports specific delivery to the tumor site of the drugs showing synergistic antitumor efficacy.
Strengths:
Weaknesses:
Patent Status:
Publications:
Anticancer Platelet-Mimicking Nanovehicles. Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Adv Mater. 2015 Nov 25;27(44):7043-50. doi: 10.1002/adma.201503323. Epub 2015 Sep 29. PMID: 26416431
Inventor Bio: Zhen Gu
http://www.bme.unc.edu/people/zhen-gu/
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: International Application
- Patent Link: https://patents.google.com/patent/WO2017027760
- Research Institute: North Carolina State University
- Disease Focus: Cancer and vascular diseases
- Basis of Invention: Sequential and site-specific delivery of multiple drugs for combined therapy using nanoparticles coated with platelet membranes (PM) with high affinity for cancer cells
- How it works: Platelet membrane-coated core-shell nanovehicle ("PM-NV") system comprising a core containing a small molecule drug, which is encapsulated by an outer shell coated with platelet membrane and carrying a second anticancer compound. PM-NV particles associate with cancer cells, delivering sequentially active compounds that act on tumor cell membrane in combination with drugs intracellularly delivered by the internalized nanoparticle core
- Lead Challenge Inventor: Zhen Gu
- Inventors: Zhen Gu, Quanyin Hu
- Development Stage: Preclinical (in vivo mouse data)
- Novelty:
- Nanoparticles encapsulated in platelet-membrane coated shells for specific delivery to cancer cells
- Nanoparticles encapsulated in platelet-membrane coated shells for specific delivery to cancer cells
Clinical Applications:
- Tumor-specific and sequential release drug delivery
- Combinatorial nanocarrier-based drug delivery
General Description:
The present invention describes the method to construct and the use of a platelet membrane-coated core-shell nanovehicle ("PM-NV") system, consisting of an inner core carrying a small molecule drug, encapsulated in outer shell coated with platelet cell membrane. Platelet is a component of the blood responsible to maintain hemostasis by preventing excessing bleeding in case of blood vessel injury. Platelets could also interact with circulating tumor cells (CTCs) and have a role in providing signals to cancer cells for efficient metastasis. Because of the high affinity between the PM and malignant cells, the PM-NV offers the advantage to specifically target cancer cells to deliver multiple and sequentially active compounds. By coating with tumor-derived PM, the nanocarriers aggregate on the surface of cancer cells. When the outer shell is associated with extracellularly active compounds, PM-NV promotes cell death signaling pathways through the interaction of these compounds with molecules that are abundant on the surface of cancer cells. The PM-NV can be internalized intracellularly by endocytosis. Upon acidity in the lyso-endosome compartment, the PM-NV are degraded releasing the second compound that could act intracellularly to induce cell death. This invention reports specific delivery to the tumor site of the drugs showing synergistic antitumor efficacy.
Strengths:
- Synergistic effect of multi-drug anti-cancer treatment
- Potentially employed to eliminate tumor cells with metastatic capability
Weaknesses:
- Treatment targets mainly tumor regions but also liver and kidneys
Patent Status:
- Priority date: 2015-08-12
- Filing date: 2016-08-12
- Publication date: 2017-02-16
Publications:
Anticancer Platelet-Mimicking Nanovehicles. Hu Q, Sun W, Qian C, Wang C, Bomba HN, Gu Z. Adv Mater. 2015 Nov 25;27(44):7043-50. doi: 10.1002/adma.201503323. Epub 2015 Sep 29. PMID: 26416431
Inventor Bio: Zhen Gu
http://www.bme.unc.edu/people/zhen-gu/
